Pandemic Digital Memorial concludes its first phase - Pan American Health Organization (PAHO)

Health authorities approved new regional strategies to strengthen preparedness for health emergencies, tackle antimicrobial resistance, curb dengue and other arboviral diseases, and improve food safety, while advancing access to vaccines, medicines and other essential health technologies across the Americas. Washington, D. C., 2 October 2026 (PAHO) – The 63rd Directing Council of the Pan American Health Organization (PAHO) concluded with countries of the Americas approving a series of decisions aimed at strengthening preparedness for increasingly frequent health emergencies, addressing antimicrobial resistance, reducing the growing burden of dengue and other arboviral diseases, improving food safety, and expanding access to health technologies. Over five days, Ministers of Health and other senior health authorities from across the Americas met in Washington, D. C., to discuss key public health priorities, review progress on regional initiatives and adopt decisions aimed at strengthening health systems and advancing health and well-being across the Region. “The resolutions and decisions adopted during this Council will guide our work in the years ahead.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.